4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Thursday, MarketBeat reports. They currently have a $36.00 target price on the stock. HC Wainwright‘s price target indicates a potential upside of 233.18% from the stock’s previous close.
FDMT has been the topic of a number of other reports. The Goldman Sachs Group restated a “buy” rating and issued a $32.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, August 13th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Thursday, October 15th. B. Riley Financial restated a “buy” rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. Bank of America raised their price objective on shares of 4D Molecular Therapeutics from $29.00 to $33.00 and gave the company a “buy” rating in a report on Tuesday, September 29th. Finally, Cantor Fitzgerald upgraded shares of 4D Molecular Therapeutics from a “neutral” rating to an “overweight” rating and set a $20.00 price objective on the stock in a report on Monday, September 14th. Eleven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $28.90.
View Our Latest Research Report on 4D Molecular Therapeutics
4D Molecular Therapeutics Stock Up 0.0%
4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. The firm had revenue of $3.78 million during the quarter, compared to analyst estimates of $3.62 million. Equities research analysts expect that 4D Molecular Therapeutics will post -4.14 earnings per share for the current year.
Insider Buying and Selling
In related news, insider David Kirn sold 58,333 shares of 4D Molecular Therapeutics stock in a transaction on Monday, October 5th. The shares were sold at an average price of $12.92, for a total transaction of $753,662.36. Following the sale, the insider directly owned 709,153 shares in the company, valued at $9,162,256.76. This trade represents a 7.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders have sold 136,205 shares of company stock worth $1,780,316. 7.90% of the stock is owned by company insiders.
Institutional Investors Weigh In On 4D Molecular Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of FDMT. Toth Financial Advisory Corp acquired a new stake in 4D Molecular Therapeutics during the 3rd quarter worth $29,000. Opaleye Management Inc. increased its stake in 4D Molecular Therapeutics by 197.8% in the second quarter. Opaleye Management Inc. now owns 334,437 shares of the company’s stock valued at $4,448,000 after purchasing an additional 222,146 shares during the period. Engineers Gate Manager LP increased its stake in 4D Molecular Therapeutics by 132.0% in the second quarter. Engineers Gate Manager LP now owns 68,206 shares of the company’s stock valued at $907,000 after purchasing an additional 38,806 shares during the period. AXQ Capital LP acquired a new position in 4D Molecular Therapeutics in the second quarter valued at $186,000. Finally, Headlands Technologies LLC increased its stake in 4D Molecular Therapeutics by 20.6% in the second quarter. Headlands Technologies LLC now owns 19,238 shares of the company’s stock valued at $256,000 after purchasing an additional 3,282 shares during the period. 99.27% of the stock is currently owned by institutional investors and hedge funds.
4D Molecular Therapeutics Company Profile
4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to design adeno-associated virus (AAV) vectors intended to deliver genetic medicines to specific tissues and organs.
Its pipeline has focused primarily on ophthalmology and pulmonology. Key investigational programs have included 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema, and 4D-710, an inhaled gene therapy designed to address the underlying cause of cystic fibrosis in patients who cannot benefit from existing CFTR modulator treatments.
See Also
- Five stocks we like better than 4D Molecular Therapeutics
- Not All Tech Is Getting Crushed: 5 Names Holding Up Through the AI Sell-Off
- Actively Managed ETFs Are Giving In to the Price War—To the Benefit of Investors
- Valero’s Windfall Quarter Meets Washington’s Push for Cheaper Diesel
- 4 Small-Cap Stocks With Paths to Recovery After the Fed’s September Rate Hike
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
